Notably, a large cohort study by Kornelius et al. [23] found that GLP-1 analogues, particularly liraglutide and semaglutide, are associated with a 195% increased risk of depression and a 106% higher risk for suicidal ideation. This evidence concerns the gene GLP1R and depressive symptom measurement.